Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Koichi UemuraHiroki ItoRyosuke JikuyaTakuya KondoTomoyuki TatenumaTakashi KawaharaYusuke ItoMitsuru KomeyaKentaro MuraokaHisashi HasumiHiroji UemuraKazuhide MakiyamaPublished in: International journal of urology : official journal of the Japanese Urological Association (2024)
EV prolonged OS in mUC following pembrolizumab therapy in real-world data.